2012-05-24T14:57:34Z Copyright (c) 2012, The RAND Corporation RAND Corporation http://www.rand.org/topics/rheumatoid-arthritis.html http://www.rand.org/pubs/external_publications/EP20081215.html Dec 31, 2007 Dec 31, 2007

<p>Estimates the minimally important difference for a fatigue visual analog scale (VAS) using patient-reported anchors (fatigue, pain, and overall health). This information can aid in interpreting fatigue VAS in day-to-day care in clinical practice.</p>

http://www.rand.org/pubs/external_publications/EP20070103.html Dec 31, 2006 Dec 31, 2006

<p>Patients with RA have frequent encounters with multiple providers and also frequent discontinuity of care. Recognizing the complexity of the care of patients with a chronic disease across multiple dimensions provides an opportunity to better understand challenges and opportunities in delivering high quality care.</p>

http://www.rand.org/pubs/external_publications/EP20071120.html Dec 31, 2006 Dec 31, 2006

<p>The key challenge to the feasibility of arthritis performance measures is the lack of administrative data to identify the eligible population.</p>

http://www.rand.org/pubs/external_publications/EP20070615.html Dec 31, 2006 Dec 31, 2006

<p>The ACR-endorsed quality measures for RA can be assessed using available data sources. When both self-report and medical record data are used, adherence rates, designed to serve as minimum standards of care, were moderate or high for most measures. Prior to using indicators to compare quality across groups, specific strategies for operationalizing measures and for using accurate data sources to assess adherence to the measures should be defined.</p>

http://www.rand.org/news/press/2006/04/04.html Apr 4, 2006 Apr 4, 2006

April 4, 2006 News Release: RAND Study Finds Arthritis Care for Older Patients Is Poor; Lack of Information on Medication Safety Is Biggest Shortfall.

http://www.rand.org/pubs/external_publications/EP20061229.html Dec 31, 2005 Dec 31, 2005

<p>The authors conducted a prospective cohort study of rates of change in disease-modifying antirheumatic drug (DMARD) and/or systemic corticosteroid drug or dose for 568 patients with rheumatoid arthritis (RA) across 6,159 clinical encounters within 12 months to examine how changes in clinical specifications change adherence.</p>

http://www.rand.org/pubs/external_publications/EP20060217.html Dec 31, 2005 Dec 31, 2005

<p>These results support the validity and reliability of both the original CSHQ-RA and the 11-item CSHQ-RA SF when tested in a representative patient population.</p>

http://www.rand.org/pubs/external_publications/EP20050706.html Dec 31, 2004 Dec 31, 2004

<p>There is a wide diversity of research payback. Short focused project grants seem to provide value for money.</p>

http://www.rand.org/pubs/external_publications/EP20051212.html Dec 31, 2004 Dec 31, 2004

<p>To estimate weights for health states comprising American College of Rheumatology (ACR) response and different levels of adverse events associated with rheumatoid arthritis (RA) treatments.</p>

http://www.rand.org/pubs/external_publications/EP20050513.html Dec 31, 2004 Dec 31, 2004

<p>This paper studied foot pain and treatment options for children with juvenile arthritis, in particular the use of custom-made orthotics.</p>

http://www.rand.org/pubs/external_publications/EP20040324.html Dec 31, 2003 Dec 31, 2003

<p>The objectives of this study were to assess the effect of omega-3 fatty acids on 1) total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and insulin resistance in type-II diabetes and the metabolic syndrome, 2) clinical score, sigmoidoscopic score, histologic score and requirement for immunosuppressive therapy in IBD, 3) pain, swollen and tender joint counts, acute phase reactants, patient global assessment, and requirement for anti-inflammatory or immunosuppressive therapy in rheumatoid arthritis, 4) renal function, progression to end-stage renal disease, hemodialysis graft patency, mortality, and requirement for immunosuppressive therapy in renal disease, 5) disease activity, damage, patient's perception of disease activity, and requirement for immunosuppressive therapy in SLE, and 6) bone mineral density and fracture rates.</p>

http://www.rand.org/pubs/external_publications/EP20040414.html Dec 31, 2003 Dec 31, 2003

<p>These findings have important implications for health services research and quality improvement interventions pertinent to case finding for RA through self-report data.</p>

http://www.rand.org/pubs/external_publications/EP20040619.html Dec 31, 2003 Dec 31, 2003

<p>The abridged CSHQ-RA short form is a valid and reliable instrument that can be used to examine the impact of RA on patients' health-related quality of life.</p>

http://www.rand.org/pubs/external_publications/EP20040810.html Dec 31, 2003 Dec 31, 2003

<p>The case-finding method represents a promising tool for identifying RA patients, with potential application in research and quality-assurance activities.</p>

http://www.rand.org/pubs/external_publications/EP20040620.html Dec 31, 2003 Dec 31, 2003

<p>To develop systematically validated quality indicators (QIs) addressing analgesic safety.</p>

http://www.rand.org/pubs/external_publications/EP20040407.html Dec 31, 2003 Dec 31, 2003

<p>To develop a comprehensive set of explicit process measures to assess the quality of health care for osteoarthritis, rheumatoid arthritis, and analgesics use.</p>

http://www.rand.org/pubs/external_publications/EP20031216.html Dec 31, 2002 Dec 31, 2002

<p>These results support the construct validity, discriminant validity, and reliability of the CSHQ-RA as a measure that captures the impact of RA on patients' health-related quality of life.</p>

http://www.rand.org/pubs/external_publications/EP20030207.html Dec 31, 2002 Dec 31, 2002

<p>The CSHQ-RA consists of 33 items that address 5 HRQOL domains, each with high internal consistency.</p>

http://www.rand.org/pubs/monograph_reports/MR1373.html Jan 1, 2001 Jan 1, 2001

Combinatietherapie bij reumatoide artritis: Prioriteiten voor toekomstig onderzoek [Combination Therapy in Rheumatoid Arthritis: Priorities for Future Research]

http://www.rand.org/pubs/rand_europe/RE2000z14.html Dec 31, 1999 Dec 31, 1999

This review is part of a study for the Dutch Health Care Insurance Council to develop a generic method for examining combinations of medications.